These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 29528883)

  • 1. Paliperidone-Associated Atrioventricular Block.
    Yasin M; Lateef N; Pervaiz MH
    Am J Ther; 2018; 25(6):e730-e732. PubMed ID: 29528883
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral Facial Dystonia (Meige or Brueghel Syndrome) Induced by Paliperidone Palmitate.
    Marques JG
    Prim Care Companion CNS Disord; 2017 Jan; 19(1):. PubMed ID: 28129491
    [No Abstract]   [Full Text] [Related]  

  • 3. The importance of clinical observation: A case of subtle tardive dyskinesia with paliperidone palmitate.
    Omer HM; Thompson AD
    Aust N Z J Psychiatry; 2018 May; 52(5):496-497. PubMed ID: 29338294
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of Paliperidone Palmitate Throughout a Schizoaffective Disorder Patient's Gestation Period.
    Zamora Rodríguez FJ; Benítez Vega C; Sánchez-Waisen Hernández MR; Guisado Macías JA; Vaz Leal FJ
    Pharmacopsychiatry; 2017 Jan; 50(1):38-40. PubMed ID: 27414740
    [No Abstract]   [Full Text] [Related]  

  • 5. Paliperidone Injection-Associated Delayed-Onset Rash.
    Sundling K; Held J; Narang P; Lippmann S
    Prim Care Companion CNS Disord; 2019 Jan; 21(1):. PubMed ID: 30817863
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of combined paliperidone palmitate and olanzapine pamoate in resistant schizoaffective disorder.
    Legrand G; Andrianarisoa M; Mauvieux J; Jalenques I
    J Clin Psychopharmacol; 2014 Oct; 34(5):652-3. PubMed ID: 25006816
    [No Abstract]   [Full Text] [Related]  

  • 7. Paliperidone-Induced Hyponatremia.
    Tibrewal P; Dhillon R; Sharma J; Bastiampillai T
    Prim Care Companion CNS Disord; 2017 Jul; 19(4):. PubMed ID: 28767207
    [No Abstract]   [Full Text] [Related]  

  • 8. Paliperidone Palmitate-Associated Severe Refractory Tardive Dyskinesia With Tardive Dystonia: Management and Six-Months Follow-Up.
    Singh S; Gupta A; Kuppili PP; Pattanayak RD; Khandelwal SK
    J Clin Psychopharmacol; 2016 Aug; 36(4):391-3. PubMed ID: 27269958
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute agranulocytosis when switching from risperidone to paliperidone.
    Wakuda T; Suzuki A; Hasegawa M; Ichikawa D; Yamasue H
    Aust N Z J Psychiatry; 2019 Jun; 53(6):586-587. PubMed ID: 30636434
    [No Abstract]   [Full Text] [Related]  

  • 10. Drugs for psychotic disorders.
    Med Lett Drugs Ther; 2016 Dec; 58(1510):160-164. PubMed ID: 27960194
    [No Abstract]   [Full Text] [Related]  

  • 11. A patient with multiple episodes of rhabdomyolysis induced by different neuroleptics.
    Aggarwal R; Guanci N; Marambage K; Caplan JP
    Psychosomatics; 2014; 55(4):404-408. PubMed ID: 24016383
    [No Abstract]   [Full Text] [Related]  

  • 12. Risperidone-Associated Atrioventricular Block.
    Jegede O; Taher K
    Am J Ther; 2019; 26(5):e610-e612. PubMed ID: 29927774
    [No Abstract]   [Full Text] [Related]  

  • 13. In vivo analysis of torsadogenic potential of an antipsychotic drug paliperidone using the acute atrioventricular block rabbit as a proarrhythmia model.
    Hagiwara M; Kambayashi R; Aimoto M; Nagasawa Y; Takahara A
    J Pharmacol Sci; 2016 Sep; 132(1):48-54. PubMed ID: 27262905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late-onset Neuroleptic Malignant Syndrome Associated With Paliperidone Long-acting Injection and Lithium: A Case Report.
    Netcheva Z; Shin K
    J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):333-335. PubMed ID: 33605644
    [No Abstract]   [Full Text] [Related]  

  • 15.
    Naguy A; Al-Khadhari S
    Psychopharmacol Bull; 2024 Jul; 54(3):100-102. PubMed ID: 38993660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lithium carbonate as a treatment for paliperidone extended-release-induced leukopenia and neutropenia in a patient with schizoaffective disorder; a case report.
    Matsuura H; Kimoto S; Harada I; Naemura S; Yamamuro K; Kishimoto T
    BMC Psychiatry; 2016 May; 16():161. PubMed ID: 27229149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder.
    Joshi K; Lin J; Lingohr-Smith M; Fu DJ
    J Med Econ; 2015; 18(8):629-36. PubMed ID: 25800457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study.
    Ravenstijn P; Remmerie B; Savitz A; Samtani MN; Nuamah I; Chang CT; De Meulder M; Hough D; Gopal S
    J Clin Pharmacol; 2016 Mar; 56(3):330-9. PubMed ID: 26189570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation.
    Mauri MC; Reggiori A; Paletta S; Di Pace C; Altamura AC
    Expert Opin Drug Saf; 2017 Mar; 16(3):365-379. PubMed ID: 28140680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paliperidone-induced rhabdomyolysis: a case report.
    Fernández-Macho JG; Espárrago-Llorca G; Morales-Gómez GR; Guisado-Macías JA
    Actas Esp Psiquiatr; 2015; 43(2):66-8. PubMed ID: 25812544
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.